Zealand Pharma

Zealand Pharma A/S is a biotechnology company that discovers, designs, and develops peptide-based medicines for the treatment of gastrointestinal, metabolic, and other speciality diseases.In August 2019, the company announced to relocate its new corporate headquarters to Sydmarken 11 in Søborg.In February 2020, Zealand Pharma reported a bid to acquire substantially all assets from Valeritas Holdings for a total cash consideration of $23 million and the assumption of certain liabilities related to the ongoing business, pursuant to the terms of the "stalking horse" asset purchase agreement entered into with Valeritas. On February 9, 2020, Valeritas and its subsidiaries filed voluntary petitions in theUS Bankruptcy Court for the District of Delaware. At that time, Zealand entered into a definitive agreement to acquire substantially all assets from Valeritas. Under the terms of the agreement, Zealand served as the stalking horse bidder in a sale process. The proposed sale was to be conducted through